Butrans Patch, Extended Release
NDC Package 59011-751-04
Package Information
Butrans (buprenorphine) patches is bUTRANS is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.Limitations of UseBecause of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1)], reserve opioid analgesics, including BUTRANS, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.BUTRANS is not indicated as an as-needed (prn) analgesic. This formulation utilizes a patch, extended release delivery system. Marketed by Knoa Pharma Llc, this product is identified by NDC 59011-751 and is authorized under FDA application NDA021306.
Identification & Billing
- RxCUI: 1432969 - buprenorphine 15 MCG/HR 7 Day Transdermal System
- RxCUI: 1432969 - 168 HR buprenorphine 0.015 MG/HR Transdermal System
- RxCUI: 1432969 - buprenorphine 15 MCG/HR Weekly Transdermal Patch
- RxCUI: 1432971 - Butrans 15 MCG/HR 7 Day Transdermal System
- RxCUI: 1432971 - 168 HR buprenorphine 0.015 MG/HR Transdermal System [BuTrans]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59011 - Knoa Pharma Llc
- 59011-751 - Butrans
- 59011-751-04 - 4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 168 h in 1 PATCH
- 59011-751 - Butrans
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59011-751-04 identifies a specific commercial package of 4 pouch in 1 carton / 1 patch in 1 pouch / 168 h in 1 patch of Butrans, a human prescription drug labeled by Knoa Pharma Llc. This patch, extended release is formulated for transdermal use and contains buprenorphine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Knoa Pharma Llc on February 14, 2011. The current certification is valid through December 31, 2027.
How is this Knoa Pharma Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59011075104. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.